
Opinion|Videos|August 23, 2024
Management of Comment Adverse Effects Associated with mCRPC Therapies
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
Advertisement
Episodes in this series

How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA greenlights phase 1 trial of ADI-212 in mCRPC
2
Mary Dunn, MSN, RN, NP-C, OCN, on the role of APPs in genetic testing
3
State of Men’s Health Act: What urologists need to know
4
Defining High-Risk NMIBC and Diagnostic Gaps Before Referral
5









